CCIA
VYGR icon

Campbell & Co Investment Adviser’s Voyager Therapeutics VYGR Stock Holding History

Campbell & Co Investment Adviser’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-36,994
Closed -$424K – 1212
2023
Q2 		$424K Buy
36,994
+6,431
+21% +$66.5K 0.08% 509
2023
Q1 		$236K Buy
+30,563
New +$243K 0.04% 687

Other funds holding VYGR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Campbell & Co Investment Adviser's VYGR Position: Q3 2023 in Review

Campbell & Co Investment Adviser sold out of Voyager Therapeutics (VYGR) in Q3 2023, closing a stake of 36,994 shares — an estimated $424K sold.

Campbell & Co Investment Adviser first reported a position in VYGR in Q1 2023 and held it in 2 quarters. The position peaked at $424K in Q2 2023. 110 funds tracked by Wall St. Rank hold VYGR as of Q3 2023.

  • Campbell & Co Investment Adviser reported no remaining Voyager Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 36,994 Voyager Therapeutics shares in Q3 2023, an estimated $424K.
  • Campbell & Co Investment Adviser first reported a position in Voyager Therapeutics in Q1 2023 and held it in 2 quarters.
  • Campbell & Co Investment Adviser's Voyager Therapeutics position peaked at $424K in Q2 2023.
  • 110 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2023.

Based on Campbell & Co Investment Adviser's 13F filing for Q3 2023, filed 8 Nov 2023.